It is used in conjunction with neostigmine, a neuromuscular blocking reversal agent, to prevent neostigmine's muscarinic effects such as bradycardia. It is also used to reduce excessive saliva (sialorrhea), and M?ni?re's disease.
Muscarinic anticholinergic group
Glycopyrronium is a long-acting, specific antimuscarinic agent, in clinical medicine often called an anticholinergic. It has a similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, inhibition of M3-receptors at the smooth muscle results in relaxation. The high potency and slow receptor dissociation found its clinical correlate in significant and long-acting bronchodilation in patients with COPD.
Maintenance treatment of chronic obstructive pulmonary disease BY INHALATION OF POWDER Adult: 50 micrograms once daily DOSE EQUIVALENCE AND CONVERSION For inhalation of powder, each 50 microgram capsule of glycopyrronium delivers 44 micrograms of glycopyrronium.
No specific interaction studies were conducted for the co-administration of this inhalation capsule with inhaled anti-cholinergic drugs and is therefore, like for other anticholinergics, not recommended. Although no formal drug interaction studies have been performed, this inhalation capsule has been used concomitantly with other drugs commonly used in the treatment of COPD without clinical evidence of drug interactions. These include sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids. Concomitant administration of this inhalation capsule and orally inhaled indacaterol, a (32 adrenergic agonist, under steady-state conditions of both drugs does not affect the pharmacokinetics of either drug.
Arrhythmia (excluding chronic stable atrial fibrillation) . history of myocardial infarction . history of QT-interval prolongation . left ventricular failure . unstable ischaemic heart disease
Common or very common Insomnia Uncommon Epistaxis . hyperglycaemia . hypoaesthesia . malaise . Rhinitis
PREGNANCY Manufacturer advises use only if potential benefit outweighs risk. BREAST FEEDING Manufacturer advises use only if potential benefit outweighs risk.
High doses of Glycopyrronium may lead to anticholinergic signs and symptoms for which, symptomatic treatment may be indicated. In COPD patients, repeated orally inhaled administration of Glycopyrronium at total doses of 100 and 200 microgram once daily for 28 days is well tolerated. Acute intoxication by inadvertent oral ingestion of glycopyrronium capsules is unlikely.
This capsule must not be swallowed. Only to be used with an inhalation device. Insert the Easycap in the Easyhaler for best performance. Remove this capsule from the blister pack immediately before using, as this capsule exposed to moisture may not tear easily. Store at a temperature not exceeding 30°C in a dry place. Protect from light & moisture.
.png&w=384&q=75)